Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

The makers of Wegovy and Zepbound are cutting prices to make the medications more affordable for people without insurance.

Merck last year signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to ...

Nessel warned Michigan residents that the dismantling of the federal Consumer Financial Protection Bureau leaves the state in ...

Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from United Biotechnology Co. Ltd. China-based ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...